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Abstract
Objectives: The aim of the study was to evaluate citation analysis as an approach to measuring core outcome set (COS) uptake, by
assessing whether the number of citations for a COS report could be used as a surrogate measure of uptake of the COS by clinical trialists.
Study Design and Setting: Citation data were obtained for COS reports published before 2010 in five disease areas (systemic sclerosis,
rheumatoid arthritis, eczema, sepsis and critical care, and female sexual dysfunction). Those publications identified as a report of a clinical
trial were examined to identify whether or not all outcomes in the COS were measured in the trial.
Results: Clinical trials measuring the relevant COS made up a small proportion of the total number of citations for COS reports. Not all
trials citing a COS report measured all the recommended outcomes. Some trials cited the COS reports for other reasons, including the
definition of a condition or other trial design issues addressed by the COS report.
Conclusion: Although citation data can be readily accessed, it should not be assumed that the citing of a COS report indicates that a
trial has measured the recommended COS. Alternative methods for assessing COS uptake are needed.  2017 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Core outcome set; Uptake; Citation analysis; Clinical trials; Systemic sclerosis; Rheumatoid arthritis; Eczema; Sepsis and critical care; Female
sexual dysfunction
1. Introduction
Inconsistency in the outcomes measured and reported
across clinical trials in the same health condition creates
difficulties for those drawing on the data produced by those
studies to make informed decisions about health care.
Variation in the outcomes selected hinders efforts to synthe-
size evidence from different trials and allows the potential
for outcome reporting bias, the reporting of a subset of the
outcomes measured based on results [1].
To help overcome these problems, the use of an agreed
standardized set of outcomes, a core outcome set (COS), is
recommended [2]. A COS consists of those outcomes
considered to be most relevant for a specific health
condition, typically agreed through consensus by a group
of key stakeholders, that should be measured and reported,
as a minimum, in all clinical trials of that condition [2].
Improving the consistency of the outcomes measured
across trials by using a COS allows evidence from trials
to be synthesized, encourages the reporting of all outcomes
and, by incorporating outcomes that are most relevant to
key stakeholders, ensures that the outcomes measured
include the most appropriate.
A systematic review published in 2014 [3] identified 250
reports relating to 198 COS, and a recent update of this
work found that the figure had increased to 227 COS by
the end of 2014 [4]. As it is evident that a large number
of published COS exist, with more than 100 also in devel-
opment, it is important to assess their uptake by clinical
trials. The continued development of COS that are not sub-
sequently used in clinical trials will contribute to, rather
than reduce, waste in research resulting from funding and
time being invested in an initiative that is not then imple-
mented. Furthermore, trials, and the eventual users of the
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What is new?
Key findings
 Core outcome set (COS) reports are mostly cited
by publications that are not reports of trials.
 Not all trials citing a COS report have measured
the outcomes in the COS.
What this adds to what was known?
 Citation analysis does not provide a reliable assess-
ment of COS uptake by trialists.
What is the implication and what should change
now?
 An efficient method to assess COS uptake based on
current data needs to be developed.
reports of those trials, will not realize the benefits that using
a COS can provide.
Assessing uptake also provides an opportunity to review
and consider revision to a COS where it is evident that a
particular outcome in the COS is not being measured or tri-
als are consistently measuring an outcome that is not
already included in the COS. Identifying COS with low up-
take provides an opportunity to address barriers and facili-
tators to uptake.
Previous work has assessed the uptake of COS by exam-
ining trial reports included in systematic reviews, or identi-
fied through literature searches, to establish whether the
outcomes in the COS were measured in the trials [5e7].
This method has proved to be resource intensive, and
because the trial report will have been published several
years after the trial’s design stage when outcomes were
chosen, it does not provide an up to date assessment of
the uptake of a COS. More recently, a study used citations
of the COS report to identify reports of trials that may have
measured the COS [8]. As with other previous work, this
study examined each individual trial report to assess uptake
of the COS making this a lengthy method. However,
citation analysis has the potential to provide an efficient
method for COS uptake assessment if the number of
citations received by a COS report alone could be taken
as an indicator of the uptake of the COS.
The aim of our study is to examine the reliability of
using citation analysis as a method of measuring COS
uptake. In any scientific publication, an author will
acknowledge the work of others by providing a reference
to their publication. The publication referenced receives
this acknowledgment in the form of a citation [9]. Citation
analysis involves counting the number of citations received
by a publication or author and taking this figure as a surro-
gate measure of impact [10], that is, the higher the citation
count, the greater the impact. Citation analysis has the
potential to provide an efficient method to assess the uptake
of a COS if the number of citations received by a COS
report could be reasonably taken as a surrogate measure
of its uptake by trialists.
2. Methods
2.1. Selection of a citation analysis tool
For this study, we selected Scopus as the citation analysis
tool. This is in keeping with a review of Scopus, Web of
Science, and Google Scholar for citation analysis, which
found that Scopus includes a wider range of journals, and
in a search for a specific publication, Scopus retrieved 20%
more citing articles than Web of Science. It was reported that
the accuracy of Google Scholar was inconsistent [11].
2.2. Identification of COS reports
Of the 250 COS reports identified in the original system-
atic review [3], 173 reports, those published in 2009 and
earlier, were considered for our citation analysis. This cut-
point was chosen to allow sufficient time for trialists to
become aware of the COS, implement it in their study,
and cite the COS report in the report of their trial by the
time of the current analysis.
2.3. Selection of COS for citation analysis
Four COS were initially selected to evaluate the suit-
ability of citation analysis for COS uptake assessment. Each
COS provided a different aspect of interest to be investi-
gated. A fifth COS was subsequently added to investigate
a hypothesis suggested by the first round of evaluation.
Appendix A at www.jclinepi.com details the characteristics
of each COS.
2.3.1. Systemic sclerosis
Systemic sclerosis was selected as a test case to assess
the methods to be used for citation analysis and the identi-
fication of trials from the citations retrieved. There are just
two COS reports for this condition [12,13], neither of which
are highly cited, and so the full process could be trialled
from start to finish relatively quickly. One of the COS
reports focused specifically on outcomes, whereas the other
considered outcomes along with other trial design issues.
2.3.2. Rheumatoid arthritis
Rheumatoid arthritis was selected as this health condition
has one of the most recognized COS that was first published
in 1993 following the 1992 OMERACT (Outcome Measures
in Rheumatology http://www.omeract.org/) conference. The
COS is reported in seven publications [14e20] all of which
were included in the analysis, along with three other publi-
cations reporting earlier suggestions of COS for the
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condition [21e23]. All ten of the COS publications focused
specifically on recommendations for outcomes. Another
reason for the selection of rheumatoid arthritis was that
the uptake of the OMERACT COS has been previously as-
sessed by examining trial reports included in Cochrane re-
views [5] to determine whether the outcomes in the COS
had been measured. We wanted to establish how many of
the trial reports that the previous study had found to have
measured the COS would have been retrieved using citation
analysis. If only a proportion of these trial reports were
retrieved this would suggest that not all trials measuring a
COS cite a COS publication in their trial report thus
bringing into question the scope of citation analysis in iden-
tifying trials that had measured a COS.
2.3.3. Eczema
Eczema was selected as this condition has a well-known
COS due to a collaborative group working specifically on
the agreement of COS in dermatological conditions,
CSG-COUSIN (https://www.uniklinikum-dresden.de/de/
das-klinikum/universitaetscentren/zegv/cousin/), which is
linked to the Cochrane Skin Group. One report relating
to the development of a COS for eczema was published
before 2009, and its focus was on recommendations for
outcomes. The report identified 20 outcome measurements
and recommended that only three of these should be used
for future studies. We assessed the uptake of the study’s
recommendations [24].
2.3.4. Sepsis and critical care
Sepsis and critical care was selected as there are two
associated COS reports, one of which specifically focused
on the selection and measurement of outcomes [25],
whereas the other considered outcomes while addressing
other clinical trial design issues [26]. As with the systemic
sclerosis example, identifying the difference in citations of
these two COS reports may offer some insight into which
type of publication is more likely to be accessed and to
have its recommendations implemented by trialists.
2.3.5. Female sexual dysfunction
Following the analysis of the first four COS, female sex-
ual dysfunction was added to the evaluation to further
investigate the level of citation of a COS report that
included recommendations for outcomes alongside recom-
mendations for other trial design issues [27].
2.4. Process
2.4.1. Citation analysis
Publications that cited at least one of the COS reports
were identified using Scopus, and the references to these
publications were exported into Microsoft Excel. Duplicate
entries of the same reference, caused by a publication citing
more than one COS report, were removed to ensure that a
reference to a COS report was not counted more than once.
A publication relating to rheumatoid arthritis that had cited
both the Felson et al. [14] and Boers et al. [17] COS re-
ports, for example, would count as one citation for the
COS.
2.4.2. Identifying RCTs
Cochrane CENTRAL (Cochrane Central Register of
Controlled Trials http://www.cochranelibrary.com/) was
used as a tool to identify which of the citing publications
were reports of trials. CENTRAL provides access to reports
of randomized and quasirandomized controlled trials
obtained from a variety of published and unpublished sour-
ces. Keywords, such as condition, intervention, and patient
population, from the title of each citing publication were
searched under the ‘‘record title’’ option in CENTRAL.
Because CENTRAL contains publications other than trial
reports, for example, systematic reviews, the abstracts of
the articles identified by CENTRAL were screened to
verify whether they were reports of trials. The full papers
of those identified as trial reports following the abstract
check were obtained for further investigation into why the
COS report was cited and whether the outcomes in the
COS were measured, to determine whether the citations
received by a COS report could be reasonably attributed
to trials measuring the COS. To confirm the eligibility of
trial reports being included in the study, and the assessment
of outcomes included in the trial by the reviewer (KB), the
reports identified for rheumatoid arthritis were cross-
checked with those identified in the previous rheumatoid
arthritis uptake study. In cases where the same reports were
identified the outcomes deemed to be measured by the trials
were compared and there was 100% agreement between the
findings of this and the previous study.
3. Results
3.1. Identifying trial reports from the citations
For each of the disease areas, the search of CENTRAL
enabled publications listed in the citation report that were
not reports of trials to be removed. The accuracy with
which CENTRAL identified trials varied between disease
areas (Table 1). CENTRAL was least accurate in identi-
fying rheumatoid arthritis trials, with 126 (53%) of the
236 publications identified by CENTRAL confirmed as
reports of trials. It was most accurate for eczema, with
six (86%) of the seven records identified being confirmed
as trial reports when the abstracts had been screened
manually.
3.2. Number of trials identified that measured the COS
Not all of the citing publications that were identified as
trials measured the recommended COS (Table 1). For three
of the disease areas (systemic sclerosis, sepsis and critical
care, and female sexual dysfunction), less than a third of
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the trials citing a COS report measured all the recommen-
ded outcomes. None of the 10 trials citing the report on
general trial design issues for systemic sclerosis measured
the COS, 25% of the four trials citing the COS-only report,
and none of the 13 trials citing the general trial design is-
sues report for sepsis and critical care measured the COS
and 26% of the 23 trials citing the general trial design is-
sues report for female sexual dysfunction measured the
COS. In contrast, 78% of the 126 trials citing a COS-only
report for rheumatoid arthritis measured all the outcomes
in the COS and all six trials citing the outcomes-only
report for eczema followed its recommendations on
outcomes.
Assessment of a random sample of trial reports that
had cited a COS report but did not measure all the recom-
mended outcomes (a maximum of five reports for each
condition and type of COS report, where available)
identified a variety of reasons for citing the COS report
(Table 2). Few of the trials were citing the COS report
in relation to outcomes. The majority were referencing
recommendations about other trial design issues that
had been addressed in the COS report, for example,
patient inclusion criteria, or definition of a disease or dis-
order. Some of the trials referencing a COS report that
had focused only on outcomes had measured some of
the COS outcomes and cited the report for this reason
but did not provide an explanation for not measuring all
of the recommended outcomes.
3.3. Type of COS report cited in trial reports
For disease areas where two types of COS report exist,
that is, reports focusing only on outcomes and reports
considering outcomes while addressing other clinical trial
Table 1. Figures from citation analysis for each disease area
















COS-only 27 1 0 0 (0) 0
General design issues 97 15 10 0 (0) 10
Rheumatoid
arthritis
COS-only 1,472 236 126 98 (78) 9
Eczema COS-only 136 7 6 6 (100) 4
Sepsis and
critical care
COS-only 64 4 4 1 (25) 6
General design
issues





723 40 23 6 (26) 3
Abbreviation: COS, core outcome set.
Table 2. Reasons that trials not measuring the COS cited COS reports
Disease area Reason for citing COS report
Systemic sclerosis
(general trial design issues report)a
Acknowledging that clinical trials are recognized to be difficult in the disease area
Patient inclusion criteria (two trials)
Patient population
Determination of disease onset
Rheumatoid arthritis
(COS-only reports)
Acknowledged COS but limited the number of outcomes to three that could be obtained
by self-assessment by the patients
The patient’s global status and level of overall pain and the physician’s global assessment
were scored on a visual analogue scale.
Measured the core set of measures apart from radiographs in trial lasting more than 1 year.
The trialists acknowledged that this should be done in future trials.
The variables chosen included 4 of 7 measures proposed for assessing disease
activity by the ACR in 1993.
Problems with outcomes have been addressed with the development of a COS
Sepsis and critical care
(COS-only report)b
Named some of the proposed COS outcomes
Inflammatory markers can provide additional support for a phase III study
Sensitivity of organ dysfunction scales
Sepsis and critical care
(general trial design issues report)
Definition of sepsis (four trials)
Patient inclusion criteria
Female sexual dysfunction
(general trial design issues report)
Definition of female sexual arousal disorder (three trials)
Definition of hypoactive sexual desire disorder (two trials)
Abbreviation: COS, core outcome set.
a There were no citing trials for the systemic sclerosis COS-only report so no sample available.
b Three citing trials were available for the sepsis and critical care COS-only report that did not measure the COS.
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design issues, the general design issue reports received
more citations from trials (systemic sclerosis n5 10, sepsis
and critical care n 5 13) than the outcomes specific reports
(systemic sclerosis n 5 0, sepsis and critical care n 5 4).
However, none of the trials citing the general design issues
papers measured the outcomes recommended. Although
the COS-only reports for these disease areas also had a
low number of citing trials measuring the COS (systemic
sclerosis n 5 0, sepsis and critical care n 5 1), in cases
where there was only one type of report, the outcome
specific reports had considerably more citing trials that
had followed their recommendations (rheumatoid arthritis
78%, eczema 100%) than a general design issues report
(female sexual dysfunction 26%) (Table 1).
3.4. Comparison of methods of uptake assessment for
rheumatoid arthritis trials
The previous study that examined trial reports included
in Cochrane reviews to assess uptake of the OMERACT
COS [5] found that 100 of the 350 trials that were identified
measured all the outcomes in the COS. When the 350 trial
reports were cross-referenced with those in the citation
report, it was found that only 25 of these 350 trials had actu-
ally cited a COS report (Table 3). Therefore, for this partic-
ular sample of trials, citation analysis returned an uptake
figure of 25 out of 350 trials, whereas 100 of these 350 trials
had actually measured the outcomes in the COS. Further
comparison of the trials shows that 20 of the 25 identified
by citation analysis measured the outcomes in the COS.
3.5. Citations received from publications other than
trial reports
For each of the disease areas we assessed, a large propor-
tion of the citations received by the COS reports were from
publications reporting on something other than trials
(Table 1). For both types of COS report in all of the disease
areas, at least 90% of the citations were not from reports of
trials.
4. Conclusions
The aim of our study was to evaluate whether citation
analysis would provide an efficient method to assess COS
uptake. Although we have been able to demonstrate that
citation data can be readily accessed, further investigation
shows that it is not possible to assume that the citations
received by COS reports are from trials measuring the
COS they recommend. For example, of the 775 citations
received by the sepsis and critical care COS reports, only
17 were from trials and of these 17 trials, just one measured
the COS recommended by the report they had cited. These
figures demonstrate first that COS reports are not only cited
in trial reports but also in other types of publications and
secondly that a trial report may cite a COS report for
reasons other than adopting the COS, for example, other
aspects addressed in the COS report such as patient inclu-
sion criteria and definition of a disease. Therefore, it is
not possible to use the number of citations received by a
COS report alone as a surrogate measure for uptake of
the COS by trials. Additional steps are required to generate
an indication of uptake, as discussed below.
Further assessment of each citing publication was needed
to establish whether it is a trial report and using CENTRAL
to determine this can be a lengthy process. Keywords from
each publication title needed to be manually input, and in
cases such as the rheumatoid arthritis example, which has
1,472 records, this was time-consuming. As it is evident that
CENTRAL contains publications other than trial reports, it
is necessary to conduct further screening of abstracts to
verify those publications identified in CENTRAL. The
accuracy of CENTRAL to identify trials relies in part on
the input of individual Cochrane Review Groups, and it is
evident that there are differences in the maintenance of
records and therefore the accuracy of CENTRAL between
disease areas.
When all citing trials have been identified, an assess-
ment of the trial report is needed to determine whether all
the outcomes in the recommended COS were measured,
adding a further time-consuming stage to the process as
with other previous methods.
A recent study assessing uptake of The Prevention of
Falls Network Europe (ProFaNE) COS for fall injury pre-
vention [8] used citation analysis to identify trials citing
the report of the COS. Similar to the disease areas
reported here, a small proportion of the citations received
by the COS report were from trials, with 34 trials found in
464 citations. The 34 trials were identified by screening
the citing article’s titles and abstracts and excluding
reports that were protocols, pilot studies, or secondary
reports of a trial already extracted. Most citing articles
were observational studies (46%), editorials or reviews
(23%), or methodological articles (13%). Analysis of
the trial reports found that most trials made reference to
the COS report in relation to other recommended method-
ology, for example, length of follow-up period, rather
than outcomes. This finding is echoed in the study
Table 3. Comparison of uptake for 350 rheumatoid arthritis trials identified in Cochrane reviews
Trials identified and measuring the COS Cochrane review method Citation analysis method
No. of trials identified 350 25
No. (%) of trials that measured the COS 100 (29) 20 (6)
Abbreviation: COS, core outcome set.
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reported here, where COS reports are often referenced for
design issues that had been addressed in addition to
outcomes. Analysis of the ProFaNE COS also found that,
although most trials had reported at least one of the
recommended core domains, only one trial had reported
on all core domains.
The results of the ProFaNE COS study support our
finding that the number of citations received by a COS
report cannot be taken as an indicator of its uptake and that
further analysis is needed to ascertain whether the citing
articles are trials measuring the COS. The number of steps
and the amount of time needed to complete this process
means that citation analysis is no more efficient for uptake
assessment than the method of examining trial reports used
previously [5e7]. Rather, citation analysis provides an
alternative method of identifying trial reports that can then
be assessed. Both citation analysis studies highlight that
COS reports are mostly cited in articles that are not trial
reports and it would be of interest to further investigate
the types of articles citing COS reports and their reasons
for doing so.
In addition to these findings, there are additional limita-
tions of citation analysis for COS uptake assessment that
should be noted.
Citation analysis does not take into account those trials
that did measure the outcomes in a COS but did not cite a
COS report thus affecting the accuracy of citation anal-
ysis as an indicator of uptake. As demonstrated by the
comparison of methods to assess uptake of the rheuma-
toid arthritis COS, not all trials that measure a COS cite
a COS report. This would lead to the rate of COS uptake
being underestimated by citation analysis. In the case of
the rheumatoid arthritis COS, a study previously demon-
strated that 100 trials from a particular sample of 350
measured the COS [5]. However, when we cross-
referenced this same sample with the citation report, only
20 of the trials that had measured the COS were present,
plus a further five from the sample that had not measured
the COS. Identifying a sample of trials and taking the
number that had cited a COS report as a surrogate mea-
sure of COS uptake would remove the time-consuming
process of examining the full trial report. However, this
rheumatoid arthritis example demonstrates that uptake
rate assessed in this way could be greatly underestimated.
Regardless of which method is used to identify trials for
assessment of COS uptake, whether through Cochrane
reviews, literature searchers, or citation analysis, it is
not possible to avoid a full examination of the trial report
to obtain an accurate assessment of whether the outcomes
in the COS had been measured. Therefore, it is necessary
to consider ways in which examining trial reports can
become more streamlined. This could be achieved if the
format of trial reports allowed the outcomes measured
in the trial to be clearly annotated so that it would not
be necessary to read the full report to extract the informa-
tion required.
A further limitation of citation analysis for COS uptake
is the absence of data on the number of trials that were con-
ducted in the relevant health condition for the time period
being investigated. To make an accurate assessment of up-
take it is necessary to know the proportion of the total num-
ber of trials that used the COS. Citation analysis can only
retrieve information about trials that have cited a COS pub-
lication and does not provide the total number of trials con-
ducted as a denominator.
Along with the evaluation of citation analysis as a method
for assessing COS uptake, our findings raise an interesting
hypothesis in relation to the effect that the focus of a COS
report may have on COS uptake. Of the two COS reports
for systemic sclerosis, one considered outcomes while
addressing other clinical trial design issues [12], whereas
the other focused specifically on the selection of outcomes
[13]. Table 1 lists that none of the citing trials cited the out-
comes specific paper and although this might be expected as
that COS report was published in 2008 and the latest trial
report identifiedwas published in 2011, it generated a hypoth-
esis that a COS recommended in a general clinical trial design
publication is more likely to be implemented. However,
further investigation shows that none of the trials citing the
general clinical trial design paper measured the COS. They
had cited the paper in relation to other design issues, for
example, patient population and inclusion criteria, and not
in relation to the choice of outcomes. Further investigation
into themeasurement of outcomes in aCOS by trials that cited
a general design issues publication for female sexual dysfunc-
tion revealed that 26% of trials citing the publication
measured the COS. In contrast, 100% of trials that cited the
eczema report and 78% of trials that cited a rheumatoid
arthritis COS report, all of which focused specifically on the
selection of outcomes, followed the report’s recommenda-
tions on outcomes. It may be that when choice of outcomes
is one of several issues addressed by a report, the recommen-
dations relating to outcomesmaybecome lost in thevolume of
information provided by the publication. Trialists looking
specifically for advice on a particular area of trial design
may overlook the recommendations regarding outcomes in
these reports. Although reports focusing only on choice of
outcomesmay not be as highly cited as those covering awider
range of issues, the trialists citing these reports may be more
likely to follow the recommendations in relation towhich out-
comes to measure. This may suggest that a COS should be re-
ported independently of other design issues to attract the most
attention, but this hypothesis requires further investigation.
It would also be of interest to further investigate which
COS are measured in full, and compare their shared charac-
teristics with those of COS that are only partially measured.
This comparison may point to characteristics of COS that
could affect their uptake in full. For example, none of the
trials that cited the systemic sclerosis COS measured it in
full. However, all of the trials measured at least one of
the outcomes in the COS and the maximum measured in
any one trial was six. Appendix A shows that this particular
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COS includes 14 outcomes and its partial use may be as a
result of 14 outcomes being too many to include in a trial.
Further investigation into fully and partially measured COS
may indicate a maximum number of outcomes that should
be included to enable trials to implement the full COS.
4.1. Future work
It is important to continue to consider efficient methods
to assess the uptake of COS. Examining trial reports does
not provide an up to date picture of COS uptake, and it is
of interest to investigate methods that can identify outcomes
that trialists are choosing for their studies at the present
time, rather than those chosen at some time in the past. Clin-
ical trial registries have the potential to provide an efficient
assessment of COS uptake based on current information
about the outcomes being measured in trials. A recent
proposal suggested that trial registries could encourage tria-
lists to record their use of a COS when registering their trial
[28]. This information would provide a valuable resource
allowing uptake of COS in ongoing trials to be assessed.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2017.03.003.
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